Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients (TAMENDOX)

NCT03931928 is registered in ClinicalTrials.gov with Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) as lead sponsor.

NCT NCT03931928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03931928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients (TAMENDOX)
Lead sponsor
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Phase
Phase 2
Overall status
Completed
Start date
September 10, 2019
Completion date
May 3, 2021
Enrollment
356 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, dcis